Company Overview and News


Add MGEN
to your dashboard

Headline News

Dicerna Pharmaceuticals (DRNA): Taking Investors Down A Hole? -- 11/15/2017

10h thestreetsweeper.org
Dicerna Pharmaceuticals (DRNA) may be headed down the same hole that buried Genta, an infamous biotech darling-turned-disaster. (60-0)

miRagen Therapeutics' (MGEN) CEO William Marshall on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good afternoon ladies and gentlemen, and welcome to the miRagen Therapeutics Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, instructions will follow at that time. As a reminder, today’s call is being recorded. (43-0)

Featured Company News - Miragen Therapeutics Announces New Interim Results from Phase-1 Clinical Trial Assessing Safety and Pharmacokinetics of MRG-106

2017-10-16 accesswire
LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Miragen Therapeutics, Inc. (NASDAQ: MGEN) ("Miragen"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MGEN. The Company announced on October 13, 2017, new interim results from its ongoing Phase-1 clinical trial, designed to evaluate the safety, efficacy, and pharmacokinetics of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL). (58-0)

BRIEF-Miragen Therapeutics presents new data suggesting positive impact from systemically administered MRG-106

2017-10-13 reuters
* Miragen Therapeutics presents new clinical data suggesting positive impact from systemically administered MRG-106 on mycosis fungoides form of cutaneous T-cell lymphoma at EORTC global task force meeting (43-0)

Boulder Ventures V, L.p. opens position in MGEN / Miragen Therapeutics - Fintel.io

2017-08-16 fintel.io
August 16, 2017 - Boulder Ventures V, L.p. has filed a SC 13D/A form disclosing ownership of 82,490 shares of Miragen Therapeutics (NASDAQ:MGEN) corresponding to a(n) 0.4 ownership percentage.

miRagen Therapeutics' (MGEN) CEO William Marshall on Q2 2017 Results - Earnings Call Transcript

2017-08-12 seekingalpha
Good afternoon ladies and gentlemen, and welcome to the miRagen Therapeutics Second Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, instructions will be given at that time. As a reminder, this conference is being recorded.

CUSIP: 60463E103